Despite the progress in treatment and policy, the South Korean Dravet Syndrome market faces a significant challenge in the form of high treatment costs. The financial burden on families can be immense, as specialized medications and long-term care are expensive. This is a critical issue that payers and policymakers are grappling with. The South Korea Dravet Syndrome Market report provides insight into these payer dynamics, including the role of the national health insurance system and the need for sustainable reimbursement models. Ensuring equitable access to life-changing therapies is a key concern for the market's future.

The high cost of orphan drugs is a global issue, and South Korea is actively seeking solutions. The government is exploring different reimbursement models and public funding mechanisms to make these therapies more affordable. The goal is to balance the need to incentivize pharmaceutical innovation with the ethical imperative to provide care to those who need it most, regardless of their financial situation. The discussion around cost and access is central to the market's development and will shape its long-term sustainability and growth.